Blood glucose regulation pathway

The "Blood glucose regulation pathway" refers not to a discrete molecular target but rather an integrated set of physiological processes that maintain blood sugar within narrow limits. This system involves several key hormones—primarily insulin, glucagon, somatostatin, and amylin, all secreted by different cell types in the pancreas—as well as various transporters like GLUT family members that mediate cellular uptake of glucose. The liver plays a central role by storing excess glucose as glycogen under high-insulin conditions and releasing it during fasting via glycogenolysis stimulated by glucagon. Muscle and adipose tissue are major sites for insulin-stimulated uptake via GLUT4 transporters. Disruption at any point in this network can lead to metabolic diseases such as diabetes mellitus or hypoglycemic states[1][2][5][6]. Because it encompasses many molecules rather than one specific protein/receptor/enzyme/transporter, "blood glucose regulation pathways" should not be considered a canonical therapeutic target itself—it is instead an umbrella term describing how multiple targets interact dynamically in health and disease. The query refers broadly to "Blood glucose regulation pathways," which describes a complex physiological process rather than any individual molecule/receptor/target suitable for direct pharmacological targeting. Therefore: This entry does not correspond to one canonical molecular entity; instead it covers numerous interacting proteins/hormones/transporters involved in systemic metabolic control[1][5]. For structured data extraction purposes you should map queries like this down into their constituent actionable targets—such as "Insulin receptor," "Glucagon-like peptide 1 receptor," etc.—for which detailed information can be provided individually according to your schema.

Other names

Glucose homeostasis pathwayRegulation of blood glucoseGlucose regulatory mechanismsBlood sugar regulation pathways

Varies by drug class; examples include: Insulin analogs replace or supplement endogenous insulin to promote cellular glucose uptake[6]. Sulfonylureas stimulate pancreatic beta cells to release more insulin. GLP‑1 agonists enhance glucose-dependent insulin secretion and suppress glucagon. Each mechanism targets different nodes in the overall regulatory network.